@article{3161927,
    title = "Differential Transcriptional and Protein Expression of
Thyroid-Stimulating Hormone Receptor in Ovarian Carcinomas",
    author = "Revekka, Gyftaki and Christina, Liacos and Ekaterini, Politi and and Michalis, Liontos and Katerina, Saltiki and Theocharis, Papageorgiou and and Nikolaos, Thomakos and Dimitrios, Haidopoulos and Alexandros, Rodolakis and and Maria, Alevizaki and Aristotelis, Bamias and Athanasios, Dimopoulos and Meletios",
    journal = "International Journal of Gynecological Cancer",
    year = "2014",
    volume = "24",
    number = "5",
    pages = "851-856",
    publisher = "Lippincott, Williams & Wilkins",
    issn = "1048-891X, 1525-1438",
    doi = "10.1097/IGC.0000000000000139",
    keywords = "TSHR; Ovarian cancer",
    abstract = "Objective: Thyroid-stimulating hormone (TSH) regulates normal thyroid
function by binding to its receptor (thyroid-stimulating hormone
receptor -TSHR) that is expressed at the surface of thyroid cells.
Recently, it has been demonstrated that TSHR is abundantly expressed in
several tissues apart from the thyroid, among them the normal ovarian
surface epithelium. The role of TSHR expression outside the thyroid is
not completely understood. The current study examines possible
alterations of TSHR expression in ovarian carcinomas and its implication
in ovarian carcinogenesis.
Materials and Methods: Quantitative real-time polymerase chain reaction
and immunohistochemistry analysis of TSHR expression were performed in
34 ovarian carcinoma specimens and 10 normal ovarian tissues (controls).
Results: Significant reduction in TSHR messenger RNA (mRNA) expression
was detected in ovarian carcinomas (mean [SD]: 0.518 [0.0934] vs
normal, 49.4985 [89.1626]; P < 0.001, Mann-Whitney U test), whereas
TSHR protein levels were significantly increased (percentage of positive
cells: cancer, 73.55% [20.09%], vs normal, 54.54% [21.14%];
intensity: cancer, 2.52 [0.508], vs normal 1 [0]; P = 0.012,
Mann-Whitney U test). No significant differences in TSHR mRNA were found
according to history of thyroid disease.
Conclusions: Our study describes for the first time alterations in TSHR
expression both at mRNA and protein levels in ovarian carcinomas. The
discrepancy between the decreased levels of the TSHR mRNA and the
increased protein expression has already been described in thyroid
carcinomas and might be due to alterations in its degradation by the
ubiquitin system or other unknown mechanisms. Further analysis could
elucidate the role of these findings in ovarian carcinogenesis."
}